Azacitadine: Clinical Trials

5 trials of Azacitadine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Unknown 1
Phase 12Completed 1, Recruiting 1
Phase 31Completed 1

Follow Azacitadine: new trials by email Literature Review of Azacitadine trials Research Report on Azacitadine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Venetoclax, Azacitadine, Vorinostat - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Phase 1RecruitingMedical College of Wisconsin402023-03-312026-01-12
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
pembrolizumab, Azacitadine - Acute Myeloid Leukemia
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins672016-07-012023-03-09
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Azacitadine, Fludarabine, Cytarabine - Acute Myeloid Leukemia
Phase 3CompletedPETHEMA Foundation2892014-10-012020-04-06
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
azacitadine, venetoclax, rituximab / IDEC-C2B8 - Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
Phase 1 / Phase 2CompletedAbbVie382014-09-222021-08-02
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Vidaza and Valproic Acid - Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
Phase 2UnknownPatrick Stiff502012-01-012021-04-26

Conditions studied

Leukemia, Myeloid, Acute (5)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)

Sponsors

AbbVie (1)  ·  Medical College of Wisconsin (1)  ·  PETHEMA Foundation (1)  ·  Patrick Stiff (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Countries

United States (3)  ·  Japan (1)  ·  Spain (1)

Top investigators

Ivana Gojo, MD (1)  ·  Michael Burke, MD (1)  ·  Patrick Stiff, MD (1)  ·  Pau Montesinos, Dr (1)

Results publications

PMID 34070172, PMID 36099049